What does the publisher say about this work? According to its web-blurb:
"Public health, safety and access to reasonably priced medicine are common policy goals of pharmaceutical regulations. As both the context for innovation and competitive structure change, industry actors dynamically challenge the balance between the incentive for protection ['the incentive for protection' is what we bloggers used to term "profit" but now increasingly call "survival"] and the achievement of those policy goals.This is an enjoyable and thoroughly contemporary account of the shifts that have influenced an extremely important area of law and practice. Annoying and, in this era of computerised setting pretty well inexcusable, is the lack of a table of cases and a bibliography of materials cited by the respective authors. Not everyone reads a book from cover to cover and retains a perfect recall of the authors' sources, and this small addition would give the book an element of functionality that would greatly enhance its value.
Considering the arguments from the perspectives of innovation, competition law and patent law, this book explores the difficult question of balancing protection with access, highlighting the difficulties in harmonization and coordination. The contributors to this book, including academics, judges and practitioners from Europe, the US and Japan, explore to what extent patent strategies and life-cycle management practices take advantage of patent laws and health-care regulation and disrupt the necessary balance [this gives the game away: some might have expected the text to read "necessarily disrupt the balance" -- but that's a subject for another book ...] between incentives for innovation and access to affordable medicine and health care".
Full bibliographic information about it may be obtained from this book's web page here.